PRG Science & Technology
June 16, 2025
Company Presentation
Orphan and Rare Disease
PRG S&Tech is a company specializing in the research and development of treatments for rare genetic diseases. Developing non-marketable treatments for such diseases is inherently challenging, especially given the difficult business environment in the pharmaceutical industry. However, we are committed to honoring the dignity and value of every single life. Our mission is to develop the world’s first-in-class new drugs for patients suffering from incurable diseases and to become a company that relentlessly pursues the goal of healthy living.
Our major pipelines under development include treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS), as well as Amyotrophic Lateral Sclerosis (ALS) and Neurofibromatosis Type 2 (NF2). Furthermore, we aim to discover treatments for neurodegenerative diseases, including those related to aging and dementia, through our research on genetic diseases.
Company HQ City:
Geumjeong-gu
Company HQ State:
Busan
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
Amisodin (also known as PRG-A-05 and PRG-A) is a novel synthetic compound designed to inhibit the aggregation of superoxide dismutase 1 (SOD1), a key pathological hallmark in amyotrophic lateral sclerosis (ALS), by targeting the misfolded SOD1 protein.
Phase 1 study for healthy adults with Amisodin will be initiated to evaluate safety, tolerability, and PK profile.
CEO
Bum-Joon Park/PRG Science & Technology
Development Phase of Lead Product
Phase I
What is your next catalyst (value inflection) update?
Phase 1 with Amisodin will be completed in 1Q, 2026.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}